Title: Exacerbation of Panic Disorder with Rifampin Therapy in a Patient Receiving Citalopram
Abstract: Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 25, Issue 3 p. 435-437 Exacerbation of Panic Disorder with Rifampin Therapy in a Patient Receiving Citalopram Dr. Oladipo Kukoyi M.D., Dr. Oladipo Kukoyi M.D. Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IowaSearch for more papers by this authorDr. Tami R. Argo Pharm.D., Corresponding Author Dr. Tami R. Argo Pharm.D. College of Pharmacy, University of Iowa, Iowa City, IowaUniversity of Iowa College of Pharmacy, S443 Pharmacy Building, Iowa City, IA 52242–1112.Search for more papers by this authorDr. Ryan M. Carnahan Pharm.D., M.S., Dr. Ryan M. Carnahan Pharm.D., M.S. College of Pharmacy, University of Oklahoma, Tulsa, Oklahoma.Search for more papers by this author Dr. Oladipo Kukoyi M.D., Dr. Oladipo Kukoyi M.D. Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IowaSearch for more papers by this authorDr. Tami R. Argo Pharm.D., Corresponding Author Dr. Tami R. Argo Pharm.D. College of Pharmacy, University of Iowa, Iowa City, IowaUniversity of Iowa College of Pharmacy, S443 Pharmacy Building, Iowa City, IA 52242–1112.Search for more papers by this authorDr. Ryan M. Carnahan Pharm.D., M.S., Dr. Ryan M. Carnahan Pharm.D., M.S. College of Pharmacy, University of Oklahoma, Tulsa, Oklahoma.Search for more papers by this author First published: 16 January 2012 https://doi.org/10.1592/phco.25.3.435.61591Citations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Citalopram, a selective serotonin reuptake inhibitor, is used in the management of anxiety disorders. A 55-year-old man receiving citalopram for panic disorder reported a decrease in the agent's therapeutic efficacy when rifampin was started for osteomyelitis. His condition improved when the rifampin was stopped. Rifampin is known to induce the metabolism of cytochrome P450 3A4 substrates and thus plays a role in several drug-drug interactions. We suspect that the efficacy of citalopram was blunted with the concurrent use of rifampin. To our knowledge, only one other case of an interaction of rifampin with a selective serotonin reuptake inhibitor is described in the literature. Clinicians should monitor all drugs and dietary supplements that patients with psychiatric conditions take, regardless of the indication, intended purpose, or prescriber. This is especially important, however, for a drug that is pivotal to a patient's well-being; its therapeutic effect should be carefully monitored when any new drug is added or a change in the dosage of a concurrent drug is made. References 1 Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997; 54(4): 305–9. 10.1001/archpsyc.1997.01830160021003 PubMedWeb of Science®Google Scholar 2 Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 1998; 59(Suppl 8): 47–54. PubMedWeb of Science®Google Scholar 3 Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1998; 18(2): 345–57. 10.1002/j.1875-9114.1998.tb03861.x CASWeb of Science®Google Scholar 4 Swanberg L, Tuazon CU. Rifampin in the treatment of serious staphylococcal infections. Am J Med Sci 1984; 287(3): 49–54. 10.1097/00000441-198405000-00018 CASPubMedWeb of Science®Google Scholar 5 Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162: 985–92. 10.1001/archinte.162.9.985 CASPubMedWeb of Science®Google Scholar 6 Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol 2000; 20(1): 109–10. 10.1097/00004714-200002000-00023 CASPubMedWeb of Science®Google Scholar 7 Forest Pharmaceuticals, Inc. Celexa (citalopram hydro-bromide) package insert. St. Louis, MO; 2002. Google Scholar 8 Lake BG, Ball SE, Renwick AB, et al. Induction of CYP3A isoforms in cultured precision-cut human liver slices. Xenobiotica 1997; 27(11): 1165–73. 10.1080/004982597239921 CASPubMedWeb of Science®Google Scholar 9 Li AP, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 1997; 13: 365–74. 10.1023/A:1007451911843 CASPubMedWeb of Science®Google Scholar 10 Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 277–95. 10.1016/S0278-5846(82)80179-6 CASPubMedWeb of Science®Google Scholar 11 Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280(2): 927–33. CASPubMedWeb of Science®Google Scholar 12 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. CDER new and generic drug approvals: 1998–2004, application 20822, clinical pharmacology and biopharmaceutics review. Available from www.fda.govcderapprovalindex.htm. Assessed October 1, 2003. Google Scholar 13 Scheutz EG, Schinkel AH, Relling MV, et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996; 93(9): 4001–5. 10.1073/pnas.93.9.4001 PubMedWeb of Science®Google Scholar 14 Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97(7): 3473–8. 10.1073/pnas.97.7.3473 CASPubMedWeb of Science®Google Scholar Citing Literature Volume25, Issue3March 2005Pages 435-437 ReferencesRelatedInformation
Publication Year: 2005
Publication Date: 2005-03-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 10
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot